Short QT Syndrome (SQTS) is a novel clinical entity characterized by markedly rapid cardiac repolarization and lethal arrhythmias. A mutation in the Kir2.1 inward rectifier K + channel (D172N) causes one form of SQTS (SQT3). Pharmacologic block of Kir2.1 channels may hold promise as potential therapy for SQT3. We recently reported that the anti-malarial drug chloroquine blocks Kir2.1 channels by plugging the cytoplasmic pore domain. In this study, we tested whether chloroquine blocks D172N Kir2.1 channels in a heterologous expression system and if chloroquine normalizes repolarization properties using a mathematical model of a human ventricular myocyte. Chloroquine caused a dose-and voltagedependent reduction in wild-type (WT), D172N and WT-D172N heteromeric Kir2.1 current. The potency and kinetics of chloroquine block of D172N and WT-D172N Kir2.1 current were similar to WT. In silico modeling of the heterozygous WT-D172N Kir2.1 condition predicted that 3 µM chloroquine normalized inward rectifier K + current magnitude, action potential duration and effective refractory period. Our results suggest that therapeutic concentrations of chloroquine might lengthen cardiac repolarization in SQT3.
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Introduction
Chloroquine is an important therapeutic agent for the prevention and treatment of malaria in many parts of the world. Chloroquine is also used as adjunct therapy for treatment of systemic inflammatory disorders. Despite its widespread use, chloroquine has a narrow margin of safety, primarily as a consequence of its cardiovascular side-effects. Chloroquine prolongs cardiac action potential duration, enhances automaticity and reduces maximum diastolic potential [1] [2] [3] . As a consequence, chloroquine causes prolongation of the QT and QRS intervals on the 154 surface electrocardiogram even at therapeutic concentrations [4, 5] . These cellular and electrocardiographic side-effects are primarily due to chloroquine block of the inward rectifier K + current (I K1 ) [2, 3] , and to a lesser degree, block of the rapidly activating delayed rectifier, I Kr [2, 6] .
The Kir2.x subfamily of potassium channels (Kir2.1, 2.2 and 2.3) is responsible for cardiac I K1 , although several lines of evidence suggest that Kir2.1 is the primary channel subunit. For example, loss of function mutations in gene encoding Kir2.1 (KCNJ2), cause Andersen-Tawil Syndrome, an autosomal dominant disorder characterized by prolongation of the QT interval and ventricular arrhythmias [7, 8] . A gain of function mutation in KCNJ2 was recently reported to cause one form of Short QT Syndrome (SQT3). Priori and colleagues described a missense mutation (D172N) located within the transmembrane ion conduction pathway of Kir2.1 in a father and daughter with a short QT interval [9] . D172 is a principal binding site for Mg 2+ and polyamines which are the endogenous Kir2.1 blockers that impart the characteristic strong inward rectification property [10] . The biophysical consequences of D172 mutations have been well-characterized and include a reduction in the degree of current rectification at depolarized potentials [10] . In silico simulations of the loss of rectification predict a significant amount of repolarizing current during the terminal repolarization phase with resultant shortening of action potential duration [9] . The markedly short action potential duration provides the substrate for atrial and ventricular arrhythmias.
Given the relatively high incidence of sudden death in SQTS, an implantable cardioverter defibrillator (ICD) is considered as primary therapy [11, 12] . However, ICD therapy is expensive and particularly problematic in small children due to technical considerations. Thus, specific pharmacological therapy aimed at the molecular defect in SQTS would be beneficial. Chloroquine may be a potential therapeutic agent for treatment of SQTS3 given its known ability to block Kir2.1. We recently mapped the location of the chloroquine binding site to the cytoplasmic domain of Kir2.1 [13] . Chloroquine blocks Kir2.1 channels by plugging the cytoplasmic conduction pathway, even while polyamines remain bound to deeper sites, such as D172, within the channel vestibule. In this study, we tested experimentally whether chloroquine can effectively block D172N Kir2.1 channels and normalize repolarization duration in silico. The ability of chloroquine to block heterologously expressed D172N channels was recently reported [14] .
Materials and Methods

Molecular Biology and Cell Transfection
Kir2.1 cDNA (kind gift of C. Vandenberg) was subcloned into pcDNA3.1(+) plasmid (Invitrogen, La Jolla, CA). Mutations were made using the QuikChange Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA). The mutation was confirmed by direct DNA sequencing. Kir2.1 constructs were expressed in HEK293 cells as described [15] . A total of 5 µg DNA was transfected for inside-out and action potential voltage clamp experiments and 2.5 µg DNA for whole-cell experiments. To mimic the heterozygous state, WT and D172N Kir2.1 were coexpressed together at one-half the amounts of total transfected DNA. Cells were transfected with Lipofectamine 2000 reagent (Invitrogen) according to manufacturer instructions.
Electrophysiology
Macroscopic currents were recorded in the whole-cell and inside-out configurations of the patch-clamp technique [16] 
Drugs
Chloroquine (Sigma, St. Louis, MO) was dissolved directly in the external solution at the desired concentration. HEK293 cells were exposed to chloroquine solutions until steady-state effects were achieved. The effects of chloroquine were measured 8-10 minutes after bath application in whole cell experiments and 15 s after application in excised inside-out patches. To determine the concentration-effect relationships, a single cell was exposed to cumulative concentrations of chloroquine.
Data Analysis
Data are present as mean ± SEM (n = number of cells). ) where the test potential V, the dissociation constant at 0 mV Kd(0), valence of block z, temperature T, Faraday constant F, and gas constant R.
Action potential modeling
A mathematical model of human left ventricular myocytes [17] was used to simulate the effects of chloroquine on I K1 and action potentials. The model describes I K1 currents by:
with the conductance G K1 , the parameters P 1 and P 2 , the potassium reversal voltage E K , the transmembrane voltage V m , and the extracellular potassium concentration [K + ] o . The parameters of the I K1 model were set to resemble measured control WT, D172N and WT-D172N using mathematical optimization methods (Matlab, MathWorks, Inc., Natick, MA, USA). The model parameter temperature was set to 310 K replicating physiologic conditions of the myocyte. Although experimental measures of I K1 were performed at room temperature, no temperature scaling was necessary in the model because of the instantaneous nature of I K1 . In the myocyte model, the WT conductance G K1 was adjusted to reproduce original model action potential duration at 90% repolarization (APD 90 ). Currents for D172N and and WT-D172N channels were scaled according to measured data (Fig. 2) . The conductances G K1 at various chloroquine concentrations were calculated based on the Hill equation with parameters from Fig. 1B . The simulations with the myocyte models were carried out with the Euler method for numerical solution of ordinary differential equations [18] . The temporal discretization for solving the equations was chosen heterogeneously for various components of the model. The simulation results after the 10 th stimulation were analyzed. Action potential duration (APD) was defined as the interval between the time of maximal action potential upstroke velocity and repolarization to the level of 50% (APD 50 ) and 90% of the upstroke amplitude. The effective refractory period (ERP) was measured using a standard S1-S2 stimulation protocol: an 8-pulse conditioning train was delivered at 60 bpm, and the S1-S2 interval was shortened in 2.5 ms decrements. The ERP was defined as the longest S1-S2 interval which failed to elicit an S2 action potential of amplitude > 80% of the preceding S1 action potential.
Results
To determine the effect of chloroquine on WT and mutant Kir2.1 current in a physiologically relevant setting, we used an action potential voltage clamp protocol in the HEK293 cell heterologous expression system. The effect of chloroquine on current elicited by expression of D172N mutant Kir2.1 channels was studied, as well as coexpressed WT and D172N Kir2.1 (WT-D172N) channels to mimic the autosomal dominant nature of SQTS. In control conditions, Kir2.1 current was small during the plateau phase of the action potential, increased rapidly during the terminal phase of repolarization and declined in early diastole (Fig. 1A) . D172N and WT-D172N currents were also small during the plateau phase, but were significantly larger during the terminal repolarization and diastolic phases of the action potential (note the differences in scale bars, Fig. 1A) . Chloroquine inhibited the peak outward current in a concentration-dependent manner for WT, D172N and WT-D172N Kir2.1 (Fig.  1B) . The potency of chloroquine block was not different for WT, D172N and WT-D172N Kir2. Next, we measured the effect of chloroquine on WT and mutant Kir2.1 currents elicited by 4 s hyper-and depolarizing voltage steps between -120 and -20 mV using the whole-cell configuration. For WT Kir2.1, large inward currents, but small outward currents were elicited by this voltage protocol, as expected from a strong inward rectifier channel (Fig. 2A) . Outward current peaked at -70 mV and measured 0.10 ± 0.03 of the maximum current elicited at -120 mV. Consistent with disrupted rectification, D172N Kir2.1 outward current peaked at -60 mV and measured 0.40 ± 0.10 of the maximum current (Fig. 2B) . WT-D172N Kir2.1 current was intermediate, with outward current peaking at -70 mV and representing 0.31 ± 0.08 of maximum current at -120 mV (Fig. 2C) . Similar to WT Kir2.1, chloroquine reduced D172N and WT-D172N Kir2.1 current in a voltage-dependent manner, with preferential inhibition of outward current (Fig. 2) .
To further characterize the voltage-dependence of chloroquine block of D172N Kir2.1 channels, we used excised inside-out patches where the competing effects of endogenous blockers were absent. Application of chloroquine to the intracellular surface caused a voltageand dose-dependent reduction in outward currents (Fig.  3A, B) , similar to that reported for WT Kir2.1 [13] . We estimated the distance that chloroquine penetrates the channel pore by plotting the fraction of unblocked D172N current at various chloroquine concentrations versus membrane voltage (Fig. 3C) . Fitting the data to a Woodhull chloroquine block of WT Kir2.1 (Kd, 27 µM and z, 2.1) [13] , suggesting that the binding site for chloroquine is not appreciably altered by the D172N mutation.
Next, we determined the kinetics of onset and recovery of chloroquine block on D172N Kir2.1. The onset of chloroquine block of D172N Kir2.1 was determined by fitting current traces in Fig. 3 to a monoexponential function and plotting the inverse values (1/τ block ) versus chloroquine concentration (Fig. 4B) . Representative current traces recorded in inside-out patches elicited by voltage steps to +80, +70 and +60 mV in presence of 10 µM chloroquine and the corresponding monoexponential fits to data are shown in Fig 4A. Like WT Kir2.1, the onset of chloroquine block of D172N was concentration-and voltage-dependent. At a concentration of 10 µM, 1/τ block at +60 mV for D172N Kir2.1 channels was 36 ± 1 s -1 compared to 42 s -1
for WT Kir2.1 [13] . The time constants of chloroquine unblock (τ unblock ) of D172N Kir2.1 were also measured in excised patches (symmetrical 150 mM K + ) and in the whole-cell configuration (4mM external K + ) at variable membrane potentials (Fig. 4C and D) . Unblock of chloroquine at voltages negative to E K was voltage-and potassiumdependent with a time course similar to that for WT Kir2.1. For example, at 10 µM chloroquine in 4mM external K + , τ unblock was 1.8 ± 0.1 s at -100 mV for D172N (n = 4 cells) compared to 1.5 s for WT Kir2.1 [13] . In summary, the kinetics of the onset of chloroquine block and unblock for D172N channels were not appreciably different than that reported for WT Kir2.1.
While the action potential voltage clamp protocol provides a reasonable estimate of Kir2.1 current elicited by a physiologically relevant condition (Fig. 1) , the greater conductance of D172N and WT-D172N channels would be expected to shorten APD commensurate with the degree of altered rectification. Therefore, we used an in silico approach to further characterize the effects of chloroquine on APD and I K1 for WT and mutant Kir2.1 channels in a simulated human ventricular myocyte. The I K1 conditions were simulated by fits to the I-V relationships of the homozygous (D172N) and heterozygous (WT-D172N) mutant Kir2.1 channels (Fig.  2) . Simulated membrane voltage (Vm) for an epicardial human left ventricular myocyte in response to 1 Hz pacing frequency is demonstrated in Fig. 5 . Chloroquine caused a dose-dependent prolongation of APD 90 and reduced the peak magnitude of I K1 for the WT Kir2.1 condition (Table 1) . Under baseline conditions, APD 90 was shorter for D172N and WT-D172N conditions (0.342 and 0.358 s, respectively) relative to WT (0.383 s), consistent with the greater conductance of the mutant Kir2.1 channels. The primary effect of the D172N mutation is an alteration in the degree of rectification, with an increase in current magnitude between -80 and -40 mV (Fig. 2) . However, WT, D172N and WT-D172N Kir2.1 current fully rectifies at potentials > -20 mV (Fig. 2) . Consistent with this observation, in silico modeling revealed that the D172N mutation did not appreciably influence the plateau phase, but exerted its effect predominantly on the terminal phase of repolarization. Therefore, ADP 50 for D172N and WT-D172N conditions were similar to WT values (0.331, 0.338 and 0.340 s, respectively; Table 1 ). Similar to WT, chloroquine caused a dose-dependent prolongation of APD 90 and reduced the peak magnitude of I K1 for the D172N and WT-D172N simulations. Chloroquine also induced a dose-dependent prolongation in ERP for WT, D172N and WT-D172N conditions (Table 1) . ERP was determined by applying extrastimuli at progressively shorter intervals, until the stimulus failed to generate an action potential. ERP is a measure of cellular excitability and defines the minimum time period allowable for A direct comparison between the effects of chloroquine on the action potential properties of WT and the heterozygous mutant (WT-D172N) is presented in Fig. 6 . Chloroquine (3 µM) prolonged WT-D172N APD toward that of WT and reduced I K1 to a similar magnitude as the WT baseline condition. Thus, our in silico modeling predicts that 3 µM chloroquine blocks sufficient I K1 to normalize APD in the heterozygous SQT3 condition and restore normal ventricular excitability, as measured by ERP.
Discussion
SQTS is a sporadic or autosomal dominant disorder characterized by markedly accelerated cardiac repolarization, ventricular arrhythmias and sudden cardiac death. To date, mutations in 5 different ion channel genes (KCNH2, KCNQ1, KCNJ2, CACNA1C and CACNB2) have been identified to cause SQTS [9, [19] [20] [21] . The risk of ventricular arrhythmias and sudden death is remarkably high in SQTS with cardiac arrest reported as a presenting symptom in 31% of SQTS subjects [22] . While ICD therapy is currently recommended for primary prevention of sudden death, ICD placement is not always practical or technically feasible. Therefore, pharmacological therapy directed at the specific mutant channel underlying the various forms of SQTS is clinically important. To this end, we sought to characterize the blocking effect of chloroquine on D172N mutant channels.
Our data demonstrate that the potency for chloroquine block of WT is similar to that of D172N and WT-D172N Kir2.1 (IC 50 1.4, 1.2 and 1.5 µM). These values are qualitatively similar to that reported by El Harchi and colleagues (2.5-3 µM) for WT and D172N Kir2.1 heterologously expressed in CHO cells [14] . We further characterized the biophysical properties of chloroquine block of D172N channels and determined that the rate of onset and recovery from chloroquine block were similar to that observed in WT Kir2.1. Moreover, the estimated distance that chloroquine penetrated the D172N conduction pathway was qualitatively similar to that of WT Kir2.1. These experiments are relevant given that mutations within the Kir2.1 ion pore can affect blocker energetics over the entire distance of the ion conduction pathway [23] . Our findings confirm that the blocking properties of chloroquine are similar between WT and D172N Kir2.1 channels.
Similar to data presented by Priori and colleagues [9] , our in silico modeling predicts that the most terminal phase of repolarization is affected in the heterozygous state (WT-D172N) resulting in shortening of APD 90 , but not APD 50 . Moreover, our simulations predict that chloroquine produces a dose-dependent reduction in I K1 with resultant prolongation of APD 90 and ERP. The simulations suggest that chloroquine concentrations 3 µM are sufficient to normalize APD 90 , peak I K1 and ERP. Interestingly, plasma concentrations are typically in the range of 2-3 µM following administration of therapeutic doses of chloroquine [24] . This range of concentrations would also be expected to affect I Kr , although to a lesser degree than I K1 [2] . The combination of I K1 and I Kr blockade might result in a greater degree of APD prolongation than that predicted by our simulations. Clearly, there are limitations inherent in this study which precludes the direct comparison of our experimental findings with the use of chloroquine for treatment of SQT3. However, our results and those of El Harchi and colleagues [14] provide a proof of principle foundation for a carefully controlled clinical trial.
